Tilray just showed how fast a policy trade can cool off

Tilray Brands (TLRY) surged in premarket trading on fresh enthusiasm over marijuana rescheduling, then gave back much of the move as the session unfolded. The early excitement followed a U.S. government shift to reclassify certain marijuana products and a market rush into cannabis names.

By later in the day, that rally had cooled as traders worked through the scope of what had actually changed. Reuters reported that cannabis shares initially jumped and then fell back, with stocks including Tilray reversing after investors recognized the move applied only to FDA-approved and state-licensed medical cannabis products, not the broader adult-use market.

That made Tilray's move a sharper version of a pattern cannabis investors know well. Policy headlines can move the group quickly, but the details often end up deciding whether gains stick.

The government action on cannabis was narrower than the headline

The U.S. Department of Justice said it would reclassify FDA-approved and state-licensed medical cannabis products to Schedule III. Reuters reported that the shift could improve access to research, reduce some tax burdens, and help medical cannabis operators on the margins. It did not legalize marijuana nationally, and it did not resolve the broader federal conflict around adult-use cannabis.

The federal process is also still unfolding. The DEA's proposed rescheduling page shows the rulemaking has been active for months, and the agency separately said a hearing on the proposed rescheduling of marijuana was postponed in January 2025 pending further proceedings. That leaves the market dealing with a process story as much as a policy story.

More cannabis:

• Cannabis stocks get boost from good news out of the Biden administration
• Wellness retailer files Chapter 11 bankruptcy amid rising debt
• KFC, Wingstop, and more roll out promotions for 4/20

Those limitations help explain why the rally lost momentum. Traders reacted to the possibility of a more favorable federal posture, only to face the reality that the near-term commercial impact still looks concentrated in medical cannabis and remains tied to further regulatory steps.

Tilray does have a real medical-cannabis angle

In its fiscal second-quarter 2026 results, the company said federal rescheduling would be "an important advancement for medical cannabis in the United States" and argued that it already has the infrastructure to pursue that opportunity.

Tilray pointed to Tilray Medical U.S., an expected $150 million global medical cannabis business, and a $300 million Tilray Pharma medical distribution platform as the foundation for a repeatable U.S. medical model.

That gives the stock a more credible U.S. medical thesis than a pure speculation trade. The company has been trying to position itself for years around regulated medical markets, and its January release made clear that management sees federal rescheduling as an opening to expand research, patient access, and product development in the U.S.

Tilray's core business had already been improving

The company's recent fundamentals also help explain why investors were quick to chase the move. Tilray reported record fiscal Q2 2026 net revenue of $217.5 million, with international medical cannabis revenue up 36% and Tilray Pharma revenue reaching a quarterly record $85.3 million.

The company also said it had $291.6 million in cash and marketable securities, moved to a net cash position of $27.4 million, and reaffirmed fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million.

Those numbers do not solve the broader policy uncertainty, but they do give Tilray a stronger base than some cannabis peers. The company has been building a wider business that includes medical cannabis, beverage alcohol, wellness, and pharmaceutical distribution. When a policy headline hits, that broader platform can make the stock look more investable than a name with fewer operating pillars.

Tilray by the numbers

• Fiscal Q2 2026 net revenue: $217.5 million.
• International medical cannabis revenue growth: 36%.
• Tilray Pharma quarterly revenue: $85.3 million.
• Cash and marketable securities: $291.6 million.
• Net cash position: $27.4 million.
• Fiscal 2026 adjusted EBITDA guidance: $62 million to $72 million.

The stock moved faster than the policy

Tilray's rally and reversal left investors with a narrower question than the premarket action first suggested. The company still has a credible medical-cannabis setup, and the government's move could help with research, tax treatment, and legitimacy over time. The trading action showed how quickly the market can get ahead of those longer-term benefits when the actual policy opening is smaller than the first headline implies.

For Tilray, the path forward still runs through the same place management has been pointing to: regulated medical markets, pharmaceutical distribution, and enough operating discipline to stay relevant while the U.S. rulebook changes in slow motion. The rescheduling story gave the stock a spark. The fade showed that investors still want to see how much of that opportunity can actually become real.

Related: Weekly Market Wrap: Pepsi, Tilray and Nvidia

The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

This story was originally published April 24, 2026 at 7:37 AM.